Stories from Darmstadt

13.07.2020 – 20:03

Merck KGaA
Stephan Sieber Awarded EUR 1 Million Future Insight Prize 2020 by Merck

Darmstadt, Germany (ots/PRNewswire) - - Prof. Sieber is developing approaches against multi-resistant pathogens at the Technical University of Munich - Inaugural Johann Anton Merck Award presented to Prof. Caroline Dive, Cancer Research UK, for her liquid biopsy research - Sibel Health awarded the Nature Spinoff Prize Merck, a leading science and technology company, ...

more
28.05.2020 – 10:00

Merck KGaA
Merck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS

Darmstadt, Germany (ots/PRNewswire) - - Merck and Twitch collaborate on World MS Day to increase understanding of the impact of multiple sclerosis (MS) - Livestream event with Twitch influencers on May 30 will raise awareness and money for the MS International Federation and help connect people affected by the disease, in line with official World MS Day theme MS ...

more
14.05.2020 – 11:04

Öko-Institut e.V.
Close gap in the law to improve environmental standards in online shopping

Press release Freiburg/Berlin, 14 May 2020 Close gap in the law to improve environmental standards in online shopping Some sellers of electronic equipment from non-EU countries such as China who market their products on the Internet do not contribute to the costs incurred in Germany for the collection ...
One document
more
14.05.2020 – 00:23

Merck KGaA
Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020

Darmstadt, Germany (ots/PRNewswire) - - Results from two studies of BAVENCIO® to be featured in ASCO press briefing - Primary efficacy, biomarker and HRQoL analyses for tepotinib?, the first MET inhibitor to have received a regulatory approval for NSCLC with MET gene alterations - Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa? ...

more
30.04.2020 – 14:00

Merck KGaA
Data From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care

Darmstadt, Germany and New York (ots/PRNewswire) - - Not intended for US-, Canada- or UK-based media - ASCO Abstract # BAVENCIO® (avelumab): LBA1, 5061; Bintrafusp alfa (bifunctional fusion protein): 9558; Tepotinib (MET kinase inhibitor): 9556, 9575. - Late-breaking presentation of Phase III JAVELIN Bladder 100 data for BAVENCIO® showing overall survival benefit in ...

more
02.03.2020 – 08:01

Merck KGaA
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Darmstadt, Germany (ots/PRNewswire) - Approval is for ERBITUX® in combination with platinum-based therapy with fluorouracil for the first-line treatment of R/M SCCHN Pivotal Phase III study shows significant improvements with ERBITUX® in combination with platinum-based therapy with fluorouracil in response rate, ...

more
27.11.2019 – 11:27

Fraunhofer-Institut für Sichere Informationstechnologie SIT
New Award for excellent Cybersecurity Research / Fraunhofer CyberStar Award selects the best theses

Darmstadt (ots) - The Fraunhofer Institute for Secure Information Technology SIT launches the CyberStar Award for Excellent Research Students to promote graduates and students in applied cybersecurity and privacy in Israel. The Fraunhofer CyberStar Award recognizes outstanding theses with a cash prize up to 5000 USD ...

more
20.11.2019 – 08:01

Merck KGaA
Merck Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations

Darmstadt, Germany (ots/PRNewswire) - - Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients in Japan, and for which significant unmet medical need exists - MET exon 14 (METex14) skipping alterations and MET amplifications are present in ...

more
05.11.2019 – 14:22

Fraunhofer-Institut für Sichere Informationstechnologie SIT

Fraunhofer SIT Finds Serious Security Flaws in TwitterKit for iOS

more
30.10.2019 – 19:08

Technische Universität München
Insect decline more extensive than suspected

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35768/ High resolution images: https://mediatum.ub.tum.de/1522699 NEWS RELEASE Insect decline more extensive than suspected Causes of insect decline and biodiversity loss to be found at the landscape level ...

more
28.10.2019 – 19:00

Merck KGaA
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

Darmstadt, Germany, and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen ...

more
24.10.2019 – 14:00

Fraunhofer-Institut für Sichere Informationstechnologie SIT

New code scanner finds software vulnerabilities without source code

more
18.10.2019 – 07:30

creditshelf
SME study: Companies wish for new financing models

Frankfurt (ots) - Nine out of ten medium-sized industrial companies would find a financing model attractive in which the loan conditions are not primarily determined by historical financial ratios and available collateral, but by data that substantiates the performance of the investment and makes it verifiable at any time. The willingness to make the corresponding data available to lenders is high. These are the results ...

more
08.10.2019 – 08:12

Deutsche Telekom AG

it-sa 2019: The Global Guardian never sleeps

more
27.09.2019 – 08:01

Merck KGaA
Abstracts highlight data on BAVENCIO as a monotherapy and in combination in multiple advanced cancers

Darmstadt, Germany, and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part of combination regimens for the ...

more
23.09.2019 – 08:01

Merck KGaA
New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: ...

more
20.09.2019 – 14:10

Merck KGaA
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

Darmstadt, Germany and New York, Us (ots/PRNewswire) - Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission ...

more
11.09.2019 – 08:30

Merck KGaA
Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

Darmstadt, Germany (ots/PRNewswire) - - Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis - The ...

more
09.09.2019 – 14:00

Merck KGaA
Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

Darmstadt, Germany (ots/PRNewswire) - - Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation and select MET dysregulations The ...

more
22.08.2019 – 12:36

Technische Universität München
Temperatures of 800 billion degrees in the cosmic kitchen

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10516 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35655/ High-resolution Pictures: https://mediatum.ub.tum.de/1518458 NEWS RELEASE Temperatures of 800 billion degrees in the cosmic kitchen HADES experiment simulates colliding and merging neutron stars It is ...

more
14.08.2019 – 12:32

Fraunhofer-Institut für Sichere Informationstechnologie SIT

Danger over the phone / Researchers at Fraunhofer SIT find serious security flaws in VoIP telephones

more
02.08.2019 – 08:00

Sysmex Inostics GmbH
Sysmex obtains Japanese manufacturing and marketing approval for the first blood-based RAS mutation testing for colorectal cancer

Kobe, Japan (ots) - Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBEAM(TM) RAS CRC Kit, used for blood-based circulating tumor DNA (ctDNA) molecular testing of mutations in the RAS gene for advanced colorectal cancer patients. With clinically-validated high sensitivity and ...

more
22.07.2019 – 13:00

Messe Erfurt

Start-ups point the way in the 3D printing industry

Here you can download the press release:
One document
more
11.07.2019 – 13:45

BAM Bundesanstalt für Materialforschung und -prüfung

BAM investigates the use of earth block masonry for sustainable housing construction

more
26.06.2019 – 14:22

Messe Erfurt

5
Quantum leaps in medicine and other innovations through additive manufacturing

Here you can find our press release as pdf download:
One document
more
24.06.2019 – 14:00

Merck KGaA
Merck to Showcase New Data Across MS Portfolio at EAN 2019

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK or U.S. based media - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib at the 5th Congress of the European Academy of Neurology - Presentations include new data on the long-term efficacy and safety of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis from the Phase 2 ...

more
18.06.2019 – 10:41

INDICS

2
CASIC launches CASICloud INDICS

more

12345678Next